Divestment

Kuros

Orthobiological products for tissue and fracture repair.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Switzerland
Fund: LSP 5
Entry: 2015
Exit: 2024
Website: Kuros

Kuros

Responsible Partner

Christoph Broja

Christoph Broja

Partner

News

April 7, 2026
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

Do You Want to Know More?

We are eager to explore how we can achieve great things together.